Life Sciences

The June 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The May 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The April 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The March 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The February 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The January 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Cheryl Reicin, International Chair of Life Sciences, shares her perspectives on this year’s JPM Healthcare Conference, that reflected renewed optimism in life sciences dealmaking, with strong public‑market activity and growing interest in key subsectors.

The December 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The November 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The October 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The September 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

The August 2025 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors. Responding to President Trump’s executive order on reducing regulatory burdens, FDA announced the PreCheck program, with the goal of accelerating onshoring of drug manufacturing. FDA, HHS, and USDA have issued a joint request for data and information to develop a uniform definition of ultra-processed foods (UPF). FDA held a public meeting on August 4 to start negotiation for reauthorizing the Medical Device User Fee Amendments (MDUFA), providing a look at what stakeholders hope to achieve in terms of FDA commitments and performance goals. In July, FDA announced that it is revoking 52 individual “obsolete and unnecessary” food product standard-of-identity (SOI) regulations.

The July 2025 edition of FDA in Flux highlights five significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.

Welcome to FDA in Flux – A Mintz newsletter tracking rapid changes in policy and agency actions that impact medical, life sciences, and consumer product investment decisions and development strategies.

Employers and company owners should stay informed of the 2025 life science dealmaking trends. In a series of videos, International Chair of Life Sciences Cheryl Reicin provides valuable commentary on Big Pharma M&A, deal drivers, patent cliff impacts, and emerging sectors.

Read about the new accelerated filing deadlines for ownership reporting on Schedule 13G that take effect on September 30, 2024 and the requirements for different types of investors.

On March 18, President Biden signed an executive order (EO) that contributes to the administration’s objective to create solutions to long-lasting women’s health issues that have been historically understudied and under-evaluated.